RxDoctor Payments DataLook up a doctor →

Pamela Desilva, MD

Internal Medicine · Palmdale, CANPI 1568414548

Payments from drug & device makers

$2,595,609in general payments, 2019–2025

Across 425 payments — averaging $6107.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$998K
  • Pfizer$847K
  • Merck$625K
  • Bavarian Nordic A/s$66K
  • Cleerly, Inc.$26K
  • Currax Pharmaceuticals LLC$23K
  • plus $9K from 12 others

What the payments were for

  • Food & beverage$863100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,595,609 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$562,273
Medicare patients
478
Services billed
5,100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide115$165,533
JardianceEmpagliflozin93$101,980
MounjaroTirzepatide28$34,995
EliquisApixaban24$30,434
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog37$30,001
JanuviaSitagliptin Phosphate22$25,492
ProliaDenosumab14$23,682
Repatha SyringeEvolocumab18$18,207
SynjardyEmpagliflozin/Metformin Hcl21$16,335
Synjardy XrEmpagliflozin/Metformin Hcl18$14,871
JanumetSitagliptin Phos/Metformin Hcl11$14,580
FarxigaDapagliflozin Propanediol13$14,423
LinzessLinaclotide12$12,424
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$10,125
Rosuvastatin Calcium276$5,291

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$625,014$40,07233 claims
PfizerEliquis, Paxlovid$847,492$31,86335 claims
AmgenProlia$52$23,68214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Palmdale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →